Hemmiki’s group used OAdVs (Ad5/3-Δ24aCTLA4) to express checkpoint inhibitors such as anti-CTLA4 in combination with Rb/p16-dependent CRAd and chimeric fiber [167] to observe enhanced stimulation of T-cells in patients with advanced cancer. Here, RB1 is linked to cancer.